Umbricht, D., Krljes, S., 2005. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76, 1-23.

Werber, A.E., Klein, C., Rabey, J.M., 2001. Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials. Neurol Neurochir Pol 35 Suppl 3, 37-43.

What is claimed is:

1. A method for improving cognition comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg.

2. The method of claim 1 wherein the daily dose is 1 mg or less.

3. The method of claim 2 wherein the daily dose is 0.3 mg or less.

4. A method for treating a cognitive disorder comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg.

5. The method of claim 4 wherein the daily dose is 1 mg or less.

6. The method of claim 5 wherein the daily dose is 0.3 mg or less.

7. A method for treating a disorder selected from schizophrenia, schizophreniform disorder, schizoaffective disorder, and delusional disorder comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg.

8. The method of claim 7 wherein the daily dose is 1 mg or less.

9. The method of claim 8 wherein the daily dose is 0.3 mg or less

10. A method for improving one or more of: learning, delayed memory, working memory, visual learning, speed of processing, vigilance, verbal learning, visual motor function, social cognition, long term memory or executive function comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg.

Umbricht, D., Krljes, S., 2005. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76, 1-23.

Werber, A.E., Klein, C., Rabey, J.M., 2001. Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials. Neurol Neurochir Pol 35 Suppl 3, 37-43.

What is claimed is:

1. A method for improving cognition comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg.

2. The method of claim 1 wherein the daily dose is 1 mg or less.

3. The method of claim 2 wherein the daily dose is 0.3 mg or less.

4. A method for treating a cognitive disorder comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg.

5. The method of claim 4 wherein the daily dose is 1 mg or less.

6. The method of claim 5 wherein the daily dose is 0.3 mg or less.

7. A method for treating a disorder selected from schizophrenia, schizophreniform disorder, schizoaffective disorder, and delusional disorder comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg.

8. The method of claim 7 wherein the daily dose is 1 mg or less.

9. The method of claim 8 wherein the daily dose is 0.3 mg or less

10. A method for improving one or more of: learning, delayed memory, working memory, visual learning, speed of processing, vigilance, verbal learning, visual motor function, social cognition, long term memory or executive function comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg.